Quarterly ResultMay 12, 2026, 07:32 AM
Harvard Bioscience Q1 Revenue $20.8M, Gross Margin 59%; Reaffirms FY26 Guidance
AI Summary
Harvard Bioscience reported first-quarter 2026 revenues of $20.8 million, a decrease from $21.8 million in Q1 2025, but achieved a higher gross margin of 59% compared to 56% year-over-year. The company remained profitable on an adjusted EBITDA basis at $0.8 million and is progressing with its manufacturing consolidation. Harvard Bioscience reaffirmed its full-year 2026 financial guidance, anticipating revenue growth and bottom-line improvement in the second half, driven by high-margin New Product Introduction (NPI) sales.
Key Highlights
- Q1 2026 revenue was $20.8 million, down from $21.8 million in Q1 2025.
- Q1 2026 gross margin expanded to 59% from 56% in Q1 2025.
- Q1 2026 net loss was $(3.4) million, significantly improved from $(50.3) million in Q1 2025.
- Q1 2026 adjusted EBITDA remained flat at $0.8 million.
- Cash used in operations was $(0.7) million in Q1 2026, compared to $3.0 million provided in Q1 2025.
- Reaffirmed full-year 2026 guidance: revenue growth 2-4% and adjusted gross margin 58-60%.
- Reaffirmed full-year 2026 guidance: adjusted EBITDA growth 6-10%.
- Q2 2026 revenue guidance is between $20.5 million and $22.5 million.